
    
      This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort
      Expansion (Part 2). Following determination of a recommended phase 2 dose (RP2D) in Part 1,
      the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A
      to H).
    
  